3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Multiple Myeloma
3
Lymphoma
3
Recurrence
2
Neoplasms
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, B-Cell, Marginal Zone
2
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Melanoma
1
Leukemia
1
Glioma
1
Glioblastoma
1
Diffuse Intrinsic Pontine Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Radiotherapy
6
Radiation
3
Panobinostat
3
Cyclophosphamide
3
ribociclib
2
Temozolomide
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Everolimus
2
Etoposide
2
Dasatinib
2
vandetanib
1
temsirolimus
1
spartalizumab
1
sargramostim
1
reolysin
1
pembrolizumab
1
ovex
1
marizomib
1
irinotecan sucrosofate
1
gallium maltolate
1
etoposide phosphate
1
crenolanib
1
balstilimab
1
adavosertib
1
abemaciclib
1
X-Rays
1
Vorinostat
1
Vaccines
1
Topotecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Diffuse Intrinsic Pontine Glioma
×
marizomib
×
Clear all
NCT04341311
2024-02-15
DIPG
Dana-Farber Cancer Institute
Phase 1
Terminated
4 enrolled